Servier Acquires Edgewise Muscular Dystrophy Business for $2.65B
SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...
neurological disorders
Advertisement
AbbVie Secures EU Approval for AQUIPTA as Acute Migraine Treatment
NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...
Resmed Completes Noctrix Health Acquisition to Expand Sleep Care
SAN DIEGO, June 1, 2026 Resmed has completed its acquisition of Noctrix Health, significantly expanding its clinical sleep health...
IDEAYA and Servier Report Breakthrough mUM Phase 3 Data
SOUTH SAN FRANCISCO, Calif., June 1, 2026 IDEAYA Biosciences and Servier have unveiled compelling results from the registrational Phase...
Amgen’s IMDYLLTRA Wins EU Approval for Small Cell Lung Cancer
THOUSAND OAKS, Calif., June 1, 2026 Amgen has secured a major regulatory milestone with the European Commission approval of...
Advertisements
NeuroPace Wins FDA Approval for AI-Powered Epilepsy Tool
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
Sanofi’s Venglustat Gains FDA Priority Review for GD3
PARIS, France, May 28, 2026 Sanofi has achieved a major regulatory milestone with the U.S. Food and Drug Administration...
Persistence Market Research Predicts CGRP Inhibitors Market to Reach $12.5B
London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...
Encoded Therapeutics Showcases ETX101 Data at ASGCT
SOUTH SAN FRANCISCO, Calif., April 27, 2026 Encoded Therapeutics announced its participation in the 29th Annual Meeting of the...
Rapport, Tenacia Partner to Develop RAP-219 in China
Boston, USA & Shanghai, China – March 9, 2026 Rapport Therapeutics and Tenacia Biotechnology have announced a strategic collaboration...
Advertisement
